



LKT Laboratories, Inc.

Ciprofibrate

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID C3260

CAS No. 52214-84-3

Chemical Name

Synonym

Formula $C_{13}H_{14}Cl_2O_3$

Formula Wt. 289.16

Melting Point 114-120°C


Purity ≥98%

Solubility Practically insoluble in water, freely soluble in anhydrous ethanol, soluble in toluene

Store Temp 4°C

Ship Temp Ambient

Description Ciprofibrate is a PPAR α agonist that exhibits anti-hyperlipidemic activity. Clinically, ciprofibrate decreases levels of triglycerides and total cholesterol and increases levels of HDL. In hepatoma cells, ciprofibrate increases NF- κ B DNA binding activity. Additionally, ciprofibrate induces depolarization of the mitochondrial membrane potential, which may be involved in its mechanism of enhancing peroxisome proliferation.



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
C3260	25 mg	\$60.00
C3260	100 mg	\$164.90

References Aguilar-Salinas CA, Assis-Luores-Vale A, Stockins B, et al. Ciprofibrate therapy in patients with hypertriglyceridemia and low high density lipoprotein (HDL)-cholesterol: greater reduction of non-HDL cholesterol in subjects with excess body weight (The CIPROAMLAT study). *Cardiovasc Diabetol.* 2004 Jul 23;3:8. PMID: 15272932.

Li Y, Glauert HP, Spear BT. Activation of nuclear factor-kappaB by the peroxisome proliferator ciprofibrate in H4IIEC3 rat hepatoma cells and its inhibition by the antioxidants N-acetylcysteine and vitamin E. *Biochem Pharmacol.* 2000 Feb 15;59(4):427-34. PMID: 10644051.

Zhou S, Wallace KB. The effect of peroxisome proliferators on mitochondrial bioenergetics. *Toxicol Sci.* 1999 Mar;48(1):82-9. PMID: 10330687.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.